Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2023)

Denali Therapeutics (DNLI) has 7 years of Current Deferred Revenue data on file, last reported at $1.3 million in Q2 2023.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $1.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.3 million (changed N/A YoY) and the FY2022 annual result came in at $290.1 million, up 939.06% from the prior year.
• Current Deferred Revenue eased to $1.3 million in Q2 2023 per DNLI's latest filing, from $288.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $290.1 million in Q4 2022 and bottomed at $23000.0 in Q3 2022.
• The 5-year median for Current Deferred Revenue is $21.3 million (2019), against an average of $51.1 million.
• Peak annual rise in Current Deferred Revenue reached 939.06% in 2022, while the deepest fall reached 98.26% in 2022.
• Tracing DNLI's Current Deferred Revenue over 5 years: stood at $18.7 million in 2019, then advanced by 6.27% to $19.9 million in 2020, then surged by 40.18% to $27.9 million in 2021, then soared by 939.06% to $290.1 million in 2022, then tumbled by 99.55% to $1.3 million in 2023.
• Per Business Quant, the three latest DNLI Current Deferred Revenue figures stand at $1.3 million (Q2 2023), $288.9 million (Q1 2023), and $290.1 million (Q4 2022).

Peer Comparison